CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Graaf, C. A. A.
Right arrow Articles by Kullberg, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Graaf, C. A. A.
Right arrow Articles by Kullberg, B. J.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, March 2006, p. 423-425, Vol. 13, No. 3
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.3.423-425.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Nucleotide Oligomerization Domain 2 (Nod2) Is Not Involved in the Pattern Recognition of Candida albicans

Chantal A. A. van der Graaf,1,3 Mihai G. Netea,1,3 Barbara Franke,2 Stephen E. Girardin,4 Jos W. M. van der Meer,1,3 and Bart Jan Kullberg1,3*

Departments of Medicine,1 Human Genetics, Radboud University Nijmegen Medical Center,2 Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands,3 Unité de Pathogénie Microbienne Moleculaire, Institut Pasteur, Paris, France4

Received 10 September 2005/ Returned for modification 18 October 2005/ Accepted 20 December 2005


   ABSTRACT
Top
 Abstract
Text
 References
 
Nucleotide-binding oligomerization domain 2 (Nod2) pathways are known to interact with Toll-like receptor 2 (TLR2) and TLR4, which are pattern recognition receptors for Candida albicans. We observed that the prevalence of Nod2 polymorphisms was not increased in patients with Candida infections. Candida-induced cytokine production in individuals with Nod2 polymorphisms was unaffected. We conclude that Nod2 is unlikely to play an important role in the recognition of Candida albicans.


   TEXT
Top
 Abstract
 Text
References
 
Candida albicans is a major fungal pathogen which causes invasive bloodstream infections in immunocompromised hosts (5), as well as mucosal infections, such as recurrent vulvovaginal candidiasis (RVVC) in women. Despite the importance of C. albicans in causing disease, little is known of how it is recognized by cells and how the innate immune system mounts an effective defense. Recently, a role for Toll-like receptor 2 (TLR2) and TLR4 in innate immunity against C. albicans has been established (9).

Analogous to the essential extracellular recognition functions mediated through TLRs (1), another important class of pattern recognition receptors comprises the nucleotide oligomerization domain (Nod) and caspase recruitment domain proteins, which are responsible for the intracellular recognition of microbial components like peptidoglycan (PGN) (4). It has been shown that homozygosity for the 3020insC frameshift variant of Nod2 gene is associated with decreased NF-{kappa}B translocation after stimulation with peptidoglycan, leading to a decreased proinflammatory cytokine response (3). Patients homozygous for the 3020insC frameshift mutation are at high risk for the development of Crohn's disease (10). Recent data have shown that Nod2 modulates TLR2 signaling (13), and we have demonstrated synergistic effects of Nod2 with TLR2 and TLR4 (8). We therefore hypothesized that Nod2 contributes to the recognition of C. albicans by modulating TLR2- and TLR4-dependent Candida recognition.

In the present study, we have investigated whether Nod2 is involved in the recognition of C. albicans by using two experimental approaches. We assessed the prevalence of Nod2 polymorphisms in patients with Candida bloodstream infections and in patients with RVVC and investigated the role of Nod2 in cytokine stimulation by C. albicans blastoconidia.

Nod2 genotyping. Nod2 genotyping was performed for 40 nonneutropenic individuals who had Candida bloodstream infections (defined by at least one positive blood culture and clinical signs of infection) and 15 women with recurrent vulvovaginal candidiasis who had had more than three culture-proven symptomatic episodes of a vulvovaginal Candida infection during a 12-month period. The 51 healthy volunteers were blood donors at Radboud University Nijmegen Medical Center.

DNA was extracted from whole blood by standard procedures. Genotyping was performed by multiplex pyrosequencing (11). Amplification of fragments containing the polymorphic sites 2104C->T, 2722G->C, and 3020insC was performed in multiplex with a three-primer system: a biotin-labeled universal primer (5'-biotin-GCTGCTCCGGTTCATAGATT-3') and two sequence-specific primers, one of which had a universal tail (Table 1). The 50-µl PCR mixtures contained 100 to 200 ng genomic DNA, 10 pmol of each sequence-specific primer, 1 pmol of each sequence-specific primer with a universal tail and 9 pmol of the biotin-labeled universal primer, PCR Gold Buffer (Applied Biosystems) with 2.5 mM MgCl2, 17 mM deoxynucleoside triphosphates, and 2 U Taq DNA polymerase (Applied Biosystems).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Primer sequences for detection of 2104C->T, 2722G->C, and 3020insC frameshift mutations

 
The samples were denaturated at 94°C for 10 min and then subjected to 40 cycles of amplification (94°C for 1 min, 62°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 7 min) in a PTC-200 thermal cycler (MJ Research). The genotyping results were validated by conventional sequencing.

The frequency of carriage of the Nod2 variants in patients and controls is shown in Table 2. The frequencies of Nod2 variant carriage were 17.5% among patients with Candida bloodstream infections and 20% among patients with recurrent vulvovaginal candidiasis, whereas it was 16% in healthy volunteers. We also compared the frequencies of carriage of individual Nod2 variants to the frequency data from other studies reporting on healthy Dutch volunteers (Table 2). By using Fisher's exact test, no significant differences between Candida-infected patients and the healthy control groups were observed.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Frequency of carriage of Nod2 polymorphisms in patients with Candida bloodstream infection, patients with recurrent vulvovaginal candidiasis, and healthy volunteers, as well as data from Dutch healthy controls retrieved from the literature

 
Peripheral blood mononuclear cell (PBMC) stimulation. Five healthy controls who were wild type for the Nod2 3020insC polymorphism, six patients with Crohn's disease who were wild type for the Nod2 polymorphism and four patients with Crohn's disease who were homozygous for the 3020insC polymorphism were investigated. The patients with Crohn's disease have been described earlier (8) and were not treated with medication prone to modulate cytokines (steroids, anti-tumor necrosis factor [anti-TNF]) either before or during the experiments. Mononuclear cells were isolated from peripheral blood by density gradient centrifugation over Ficoll-Hypaque (Amersham Biosciences, Sweden); washed twice in sterile phosphate-buffered saline; and resuspended in RPMI 1640 supplemented with 10 mM L-glutamine, gentamicin at 10 µg/ml, and 10 mM pyruvate. The cells were counted in a hemacytometer, and the number of cells was adjusted to 5 x 106/ml. Heat-killed C. albicans blastoconidia (107 CFU/ml, strain ATCC MYA 3573), zymosan (100 µg/ml; Sigma, St. Louis, MO), Escherichia coli lipopolysaccharide (LPS; 1 ng/ml; Sigma), and Staphylococcus aureus peptidoglycan (1 ng/ml; Sigma) were added to 5 x 105 mononuclear cells in 100 µl in a 96-well microtiter plate (Greiner, Alphen a/d Rijn, The Netherlands) and were incubated for 24 h at 37°C in a 5% CO2 atmosphere.

When the PBMCs were stimulated with purified E. coli LPS (1 ng/ml), a TLR4 ligand, the levels of production of TNF and interleukin-10 (IL-10) in the patients homozygous for the 3020insC variant did not differ from those in patients with Crohn's disease or healthy volunteers with wild-type Nod2 alleles (Fig. 1A and B). The cytokine responses by cells carrying the Nod2 frameshift mutation variant were not affected after stimulation with C. albicans blastoconidia or zymosan, a yeast cell wall particle, or TLR2 ligand. After stimulation with PGN, cells homozygous for the frameshift mutation variant showed significantly lower levels of TNF and IL-10 production compared to that by Nod2 wild-type cells (Fig. 1A, B).


Figure 1
View larger version (16K):
[in this window]
[in a new window]
  		FIG. 1. Production of TNF (A) and IL-10 (B) by the PBMCs of five healthy volunteers bearing the wild-type allele for Nod2 3020insC variant (control), six patients with Crohn's disease bearing the wild-type alleles for Nod2 3020insC variant (Nod2-WT), and four patients with Crohn's disease homozygous for this variant (Nod2-fs). The PBMCs were stimulated with E. coli LPS (1 ng/ml), S. aureus peptidoglycan (1 ng/ml), heat-killed C. albicans 107 CFU/ml, and zymosan (100 µg/ml). Data are represented as means ± standard errors of the means. *, P < 0.05, Mann-Whitney U test.

 
Stimulation of Nod1- and Nod2-transfected HEK cells. Studies examining the activation of NF-{kappa}B in cells overexpressing Nod1 and Nod2 were carried out as described previously (2). In brief, 1 x 106/ml HEK293T cells were transfected overnight with 1 ng of either Nod1 or Nod2 plus 75 ng luciferase reporter plasmid. At the same time, heat-killed Candida albicans was added to cell culture medium, and the NF-{kappa}B-dependent luciferase activation was measured following 24 h of incubation. NF-{kappa}B-dependent luciferase assays were performed in duplicate. As shown in Fig. 2, the Candida-induced stimulation of HEK cells transfected with Nod1 or Nod2 is similar to that of unstimulated cells. Muramyl dipeptide (MDP; 100 nM) and diamino pimelate-containing tripeptide muropeptide (TriDAP; 100 nM) served as control stimuli for Nod2 and Nod1, respectively.


Figure 2
View larger version (11K):
[in this window]
[in a new window]
  		FIG. 2. Stimulation of HEK cells transfected with Nod1 or Nod2. Cells were stimulated with heat-killed Candida albicans blastoconidia (5 x 105 CFU/ml and 5 x 106 CFU/ml), MDP (100 nM), and TriDAP (100 nM).

 
The innate detection of fungal products has been shown to involve both of the extracellular receptors TLR2 and TLR4. We have previously shown a role of TLR4 in disseminated Candida infections, due to decreased chemokine production and recruitment in TLR4-defective mice challenged with an intravenous Candida infection (9). In patients with a Candida bloodstream infection, we have also recently demonstrated an increased prevalence of the TLR4 Asp299Gly polymorphism, indicating that the variant of TLR4 leads to increased susceptibility to this infection (12). However, in the present study, we demonstrate that the prevalence of Nod2 polymorphisms among patients with Candida bloodstream infections and women with RVVC is similar to that among healthy volunteers. In addition, the Nod2 3020insC frameshift polymorphism does not impair cytokine release in response to C. albicans or fungal components. These data argue that Nod2 is unlikely to play a major role in susceptibility to Candida infections.


   ACKNOWLEDGMENTS
 
Mihai G. Netea was supported by a VIDI grant of The Netherlands Organization for Scientific Research.

We thank Marc Bijen for genotyping.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medicine (463), Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: 31(24)3668015. Fax: 31(24)3541734. E-mail: B.Kullberg{at}aig.umcn.nl. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782-787.[CrossRef][Medline]
  2. Girardin, S. E., I. G. Boneca, L. A. M. Carneiro, A. Antignac, M. Jehanno, J. Viala, K. Tedin, M. K. Taha, A. Labigne, U. Zahringer, A.J. Coyle, P. S. DiStefano, J. Bertin, P. J. Sansonetti, and D. J. Philpott. 2003. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300:1584-1587.[Abstract/Free Full Text]
  3. Girardin, S. E., I. G. Boneca, G. Viala, M. Chamaillard, A. Labigne, G. Thomas, D. J. Philpott, and P. J. Sansonetti. 2003. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869-8872.[Abstract/Free Full Text]
  4. Inohara, N., Y. Ogura, F. F. Chen, A. Muto, and G. Nunez. 2001. Human NOD1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276:2551-2554.[Abstract/Free Full Text]
  5. Kullberg, B. J., and A. M. L. Oude Lashof. 2002. Epidemiology of opportunistic invasive mycoses. Eur. J. Med. Res. 7:183-191.[Medline]
  6. Laine, M. L., L. S. Murillo, S. A. Morré, E. G. Winkel, A. S. Pena, and A. J. van Winkelhoof. 2004. CARD15 gene mutations in peridontitis. J. Clin. Periodontol. 31:890-893.[Medline]
  7. Murillo, L., J. B. Crusius, A. A. van Bodegraven, B. Z. Alizedeh, and A. S. Pena. 2002. CARD15 gene and the classification of Crohn's disease. Immunogenetics 54:59-61.[CrossRef][Medline]
  8. Netea, M. G., G. Ferwerda, D. J. de Jong, T. Jansen, L. Jacobs, M. Kramer, T. H. Naber, J. P. Drenth, S. E. Girardin, B. J. Kullberg, G. J. Adema, and J. W. M. van der Meer. 2005. NOD2 modulates specific TLR pathways for the induction of cytokine release. J. Immunol. 174:6518-6523.[Abstract/Free Full Text]
  9. Netea, M. G., C. A. A. van der Graaf, A. G. Vonk, C. Verschueren, J. W. M. van der Meer, and B. J. Kullberg. 2002. The role of Toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185:1483-1489.[CrossRef][Medline]
  10. Ogura, Y., D. K. Bonen, N. Inohara, D. L. Nicolae, F. F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliaskas, R. H. Duerr, J. P. Achkar, S. R. Brant, T. H. Bayless, B. S. Kirschner, S. B. Hanauer, G. Nunez, and J. H. Cho. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606.[CrossRef][Medline]
  11. Palmieri, O., S. Toth, A. Ferraris, A. Andriulli, A. Latiano, V. Annese, B. Dallapiccola, M. Vecchi, M. Devoto, S. Surrey, and P. Fortina. 2003. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin. Chem. 49:1675-1679.[Free Full Text]
  12. van der Graaf, C. A. A., M. G. Netea, S. A. Morré, M. den Heijer, P. E. Verweij, J. W. M. van der Meer, and B. J. Kullberg. Toll-like receptor 4 Asp299Gly polymorphisms are a risk factor for Candida bloodstream infection. Eur. Cytokine Netw., in press.
  13. Watanabe, T., A. Kitani, P. J. Murray, and W. Strober. 2004. NOD2 is a negative regulator of Toll-like receptor 2- mediated T helper type 1 responses. Nature Immunol. 5:800-808.[CrossRef][Medline]

Clinical and Vaccine Immunology, March 2006, p. 423-425, Vol. 13, No. 3
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.3.423-425.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Graaf, C. A. A.
Right arrow Articles by Kullberg, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Graaf, C. A. A.
Right arrow Articles by Kullberg, B. J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS